The evolving landscape of pulmonary arterial hypertension clinical trials

Nov 26, 2022

1 min read

Updated: Nov 7, 2024

In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance requires longer studies with more participants. Given that PAH is a rare disease, finding large numbers of participants is a problem. Innovative trial designs offer new options while still providing good data.

Read the original journal article

Recent Posts

Patient and Clinician Views on Shared Decision-Making

Preference for shared decision-making was nearly universal among patients and clinicians. However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%)

Why lived experience must shape research

"Drawing on decades of patient advocacy, two women living with the rare condition Congenital Melanocytic Naevus argue that lived experience must shape research from the outset, and discuss how genuine

More than half of pulmonary fibrosis patients have PH

There is not much data looking at pulmonary hypertension (PH) in interstitial lung disease, except in idiopathic pulmonary fibrosis (IPF). A study of patients with pulmonary fibrosis found that 60.7%

Comments